FAF1 Antibody / FAS-associated factor 1

Overview

FAF1 Antibody / FAS-associated factor 1 is a research-use primary antibody intended for detection of FAF1 in experimental workflows. It is supplied in Purified format. Key antibody attributes include Mouse, Monoclonal (mouse origin), clone CPTC-FAF1-2, isotype Mouse IgG2b, kappa. Applications listed for this product include WB, IHC-P. Species reactivity (as provided): Human.

Key elements and design rationale

• Target: FAF1 (FAS-associated factor 1) — selectivity and interpretation should be considered in the context of isoforms, post-translational modifications, and related family members when applicable.
• Format: Purified — format can influence background, multiplexing compatibility, and downstream detection strategies.
• Antibody identity: Mouse, Monoclonal (mouse origin), clone CPTC-FAF1-2, isotype Mouse IgG2b, kappa — these attributes help align secondary reagents and controls (e.g., isotype-matched controls) with your assay design.
• Product notes (from provided description): In contrast to growth factors which promote cell proliferation, FAS ligand (FAS-L) and the tumor necrosis factors (TNFs) rapidly induce apoptosis. Cellular response to FAS-L and TNF is mediated by structurally related receptors containing a conserved death domain and belonging to the TNF receptor superfamily. TRADD, FADD and RIP are FAS/TNF-RI interacting proteins that contain a death domain homologous region (DDH). TRADD (TNF-RI-associated death domain) and FADD (FAS-associated death domain) associate with the death domains of both FAS and TNF-RI via their DDH regions, while RIP associates exclusively with FAS. An additional FAS interacting protein designated FAF1, for FAS-associated protein factor-1, binds with the cytoplasmic tail of wildtype but not LPR mutant FAS. When overexpressed in cells, FAF1 enhances the efficiency of FAS-mediated apoptosis. In contrast to TRADD, FADD and RIP, FAF1 lacks a DDH and cannot induce apoptosis independently of FAS activation.

Where multiple assay formats are possible, align the antibody format, host/isotype, and listed applications with your detection system and controls to support clear interpretation of signal.

Biological background

In this catalog, FAF1 is positioned within Immunology & Inflammation, Tumor research contexts. For authoritative gene/protein nomenclature, domains/isoforms, and curated functional annotations, consult resources such as UniProt, NCBI Gene, and Ensembl.

Research relevance and current trends

• Higher-plex and spatially resolved readouts (e.g., multiplex IF/IHC, spatial omics) are increasing demand for well-characterized primary antibodies with clearly stated host/isotype and labeling strategies.
• Genetic perturbation controls (knockout/knockdown) and orthogonal measurements (e.g., RNA vs protein) are commonly used to strengthen target attribution when interpreting antibody-derived signals.
• Reproducibility initiatives emphasize transparent reporting of antibody identity (clone, host, isotype) and experimental context to improve cross-study comparability.

Common research applications

• WB: interpret changes in signal in the context of sample composition, epitope accessibility, and potential isoform/PTM differences across conditions.
• IHC-P: interpret changes in signal in the context of sample composition, epitope accessibility, and potential isoform/PTM differences across conditions.
• Typical workflow themes: Western blot validation, IHC on FFPE tissue, ELISA binding assay, Specificity controls.
• Workflow notes: Validate FAF1 by Western blot in cell/tissue lysates (include controls), Detect FAF1 by IHC in FFPE tissue sections (optimize antigen retrieval + dilution), Measure binding to FAF1 peptide/protein by ELISA with diluti…

When comparing conditions, consistent sample processing and appropriate negative/positive controls support interpretation of qualitative localization differences and quantitative abundance changes.

Notes for experimental interpretation

• Isoforms and post-translational modifications may shift apparent molecular weight or epitope accessibility, especially across cell states or treatments.
• Species and tissue context can affect sequence conservation, expression level, and background binding; predicted reactivity should be verified in your sample.
• Control concepts include isotype-matched controls, secondary-only controls (for indirect detection), and genetic/orthogonal controls (e.g., KO/KD, independent antibodies, or RNA measurements) when feasible.

Monoclonal and polyclonal antibodies can differ in epitope recognition breadth and lot-to-lot characteristics; consider clonality and clone information (when provided) alongside your assay requirements. Conjugated formats may simplify detection but can change background and multiplexing behavior compared with unconjugated primaries.

Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.